About Lucy Therapeutics
Lucy Therapeutics is a private company based in Waltham, Massachusetts. It has reported $28,617,503 raised in three offerings on Form D since July 2019.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 15, 2023 | Dec 26, 2023amended May 2, 2024 | $10,552,797fully sold | 6 | $1.7M | Equity, OptionsRule 506(b) | Form D/A ↗1 earlier filing |
| Dec 22, 2021 | Jan 6, 2022 | $15,044,707of $20.0M target | 5 | $3.0M | EquityRule 506(b) | Form D ↗ |
| Jun 28, 2019 | Jul 15, 2019amended Jul 22, 2020 | $3,019,999of $4.5M target | 4 | $754K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, three offerings | $28,617,503 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Lucy Therapeutics's Form D filed May 2, 2024.
RS
Rachel Sha
Director
Also a director at Axoft and Droplet Biosciences and a chief executive officer, board member at Terrestrial.
RP
Robert Poole
Director
AR
Amy Ripka
President and director
JR
John Ripple
Director
Earlier filings also listed Karoly Nikolich (director, last listed Jan 2022) and Ann DeWitt (director, last listed Jan 2022).